Table 1.

- Characteristics of 17 articles.

Studies ID	Sample sizes		Mean age (years)		Interventions		Treatment duration	PRG/CRG	Menopausal status	Endocrine therapy	Outcomes
	Trials	Controls	Trials	Controls	Trials	Controls
Yu et al5	37	38	34-52	36-53	Liuwei Dihuang pill, 30 pills bid + Jiawei Xiaoyao pill, 6g bid + TAM 10mg, bid	TAM 10mg bid	2 months	PRG	Premenopausal	Yes	Kupperman, KPS
Ren6	32	32	48 (30-60)	47 (30-60)	CHM 200ml bid + endocrine therapy	Premenopausal (TAM 10mg bid or 20mg qd, toremifene 60mg qd); postmenopausal (letrozole 2.5mg qd or anastrozole 1mg qd or exemestane 25 mg qd)	3 months	PRG	Both premenopausal and postmenopausal	Yes	Kupperman, FACT-B, E2, FSH, LH
Sun et al7	31	30	36.23±5.72	37.31±4.89	CHM 200ml bid +TAM 10mg bid	TAM 10mg bid	2 months	PRG	Premenopausal	Yes	Kupperman, E2
Zhang et al8	64	48	46.1±9.1	45.8±8.6	Xiaoyao pill 8 pills tid + Liuwei Dihuang pill 8 pills tid	Oryzanol 20mg tid	20 days	PRG	Unclear	Part of them	kupperman
Tian9	41	41	30-64	31-65	Oryzanol 20mg tid + CHM bid	Oryzanol 20mg tid	one month	PRG	Unclear	Yes	Kupperman, E2, FSH, LH
Sheng10	23	20	45-70	45-70	Oryzanol 20mg tid + VitB1 20mg tid + CHM tid	Oryzanol 20mg tid + VitB1 20mg tid	3 weeks	PRG	Postmenopausal	Yes	Kupperman, E2, LH
Sui11	29	30	45-80	45-80	Anastrozole 1mg qd or letrozole 2.5mg qd or exemestane 25mg qd + CHM bid	Anastrozole 1mg qd or letrozole 2.5mg qd or exemestane 25mg qd	2 months	PRG	Postmenopausal	Yes	Kupperman, KPS, FACT-B, CEA, CA125, CA153
Zhou et al18	25	25	44-58	43-57	Remifemin 0.28g bid + CHM bid	Remifemin 0.28g bid	3 months	CRG	Premenopausal	Unclear	E2, FSH, LH
Sun12	30	30	20-45	20-45	CHM 200ml bid	Oryzanol 20mg tid	3 months	CRG	Premenopausal	Part of them	Kupperman, E2, FSH
Wu13	36	36	31-52	31-52	Endocrine therapy + CHM 200ml bid + Tianwang Buxin Dan one pill bid	Endocrine therapy	2 months	CRG	Unclear	Yes	Kupperman, KPS, E2, FSH
Wu et al19	39	39	43-63	42-64	TAM 10mg bid + oryzanol 20mg tid + VitB1 10mg bid + CHM bid	TAM 10mg bid + oryzanol 20mg tid + VitB1 10mg bid	3 months	CRG	Unclear	Yes	E2, FSH, LH, CA125, CA153
Zhu et al14	61	60	59.43±6.4	59.7±6.61	Letrozole 2.5mg qd + CHM bid	Letrozole 2.5mg qd	2 months	CRG	Postmenopausal	Yes	Kupperman, FACT-B, CD4, CD8, CD4/CD8
Xie15	30	30	30-55	30-55	TAM 10mg bid + CHM bid	TAM 10mg bid	3 months	CRG	Premenopausal	Yes	Kupperman, KPS, E2, FSH, CD4, CD8, CD4/CD8,CEA, CA125, CA153
Guo et al20	30	30	36-72	36-72	CHM bid	Oryzanol 20mg tid	one month	CRG	Both premenopausal and postmenopausal	Unclear	E2, FSH
Xiao et al16	25	25	60.8±8.7	62.1±9.4	Letrozole 2.5mg qd + CHM bid	Letrozole 2.5mg qd + oryzanol 10mg tid	2 months	PRG +CRG	Postmenopausal	Yes	Kupperman, CA153
Liu17	22	20	67.33±5.33	68.08±4.77	Letrozole 2.5mg qd + CHM bid	Letrozole 2.5mg qd	3 months	PRG +CRG	Postmenopausal	Yes	kupperman, E2, CEA, CA125,CA153
Li et al21	25	25	53.76±8.86	54.96±8.55	Endocrine therapy + CHM bid	Endocrine therapy + alprazolam	2 weeks	CRG	Unclear	Yes	PSQI, kupperman, KPS, E2, FSH, LH

Xiao et al¹⁶ reported the outcome indicators at 4 weeks and 8 weeks, and finally included the outcome indicators at 8 weeks for meta-analysis. TAM: tamoxifen, PRG: processed Rehmannia glutinosa (Shudihuang), CRG: crude Rehmannia glutinosa (Shengdihuang), CHM: Chinese herbal medicine, KPS: Karnofsky performance status, FACT-B: functional assessment of cancer therapy - breast, E₂: estradiol, LH: luteinizing hormone, FSH: follicle stimulating hormone